|1.||Saji, Hideo: 2 articles (01/2007 - 05/2006)|
|2.||Ogawa, Kazuma: 2 articles (01/2007 - 05/2006)|
|3.||Hashimoto, Kazuyuki: 2 articles (01/2007 - 05/2006)|
|4.||Mukai, Takahiro: 2 articles (01/2007 - 05/2006)|
|5.||Chiang, Ping-Fang: 1 article (05/2013)|
|6.||Shieh, Ming-Jium: 1 article (05/2013)|
|7.||Lee, Shin-Yi: 1 article (05/2013)|
|8.||Shih, Ying-Hsia: 1 article (05/2013)|
|9.||Luo, Tsai-Yueh: 1 article (05/2013)|
|10.||Peng, Cheng-Liang: 1 article (05/2013)|
01/01/2000 - "However, in the unlikely event of balloon rupture, release of Re-188 perrhenate may cause a high radiation dose to the thyroid and stomach. "
01/01/2000 - "In this study, we compared the biodistributions of three Re-188 preparations (Re-188 perrhenate, Re-188 pentetic acid [DTPA], and Re-188 MAG3) to assess the radiation dose to organs in a rat model that mimicked balloon rupture. "
01/01/2000 - "In the event of balloon rupture, the release of Re-188 MAG3 or Re-188 DTPA results in lower radiation doses than release of Re-188 perrhenate, especially to the thyroid gland and the stomach."
11/01/1999 - "In conclusion, in the event of balloon rupture, the release of Re-188 DTPA results in lower radiation doses than Re-188 perrhenate, especially to the thyroid gland and the stomach. "
11/01/1999 - "In this study, we performed biodistribution studies of Re-188 perrhenate and Re-188 diethylenetriaminopentaacetate (DTPA) to assess the resulting organ dose values in the event of balloon rupture if these agents are used for the clinical inhibition of restenosis after percutaneous transluminal coronary angioplasty (PTCA). "
05/06/2013 - "The hydrogel after thermal transition kept the radionuclide inside the tumor, whereas free (188)Re perrhenate ((188)ReO4) diffused quickly from the tumor. "
05/06/2013 - "The residence time in the tumor was significantly longer for (188)Re-Tin loaded hydrogel than for Na (188)Re perrhenate (Na (188)ReO4). "
03/22/2007 - "Peptides with chelating domains and their oxorhenium(V) complexes were tested in vitro for binding to NCI H69 human SCLC tumor membranes. "
08/24/2006 - "The results described in this paper show that the oxorhenium(V) "3 + 1" complexes are potent, selective inhibitors of cathepsin B and have potential for the treatment of cancer."
06/01/1996 - "In vitro somatostatin receptors (SSTR)-binding affinities of P587, P829 and their oxorhenium complexes, [DTPA]octreotide and In-[DTPA]octreotide were determined in an inhibition assay using AR42J rat pancreatic tumor cell membranes and 125I-[Tyr3]somatostatin-14 as the probe. "
|4.||Neoplasm Metastasis (Metastasis)
01/01/2007 - "Previously, based on the concept of bifunctional radiopharmaceuticals, we developed a highly stable (186)Re-mercaptoacetylglycylglycylglycine (MAG3) complex-conjugated bisphosphonate, [[[[(4-hydroxy-4,4-diphosphonobutyl)carbamoylmethyl]carbamoylmethyl]carbamoylmethyl]carbamoylmethanethiolate] oxorhenium(V) ((186)Re-MAG3-HBP), for the treatment of painful bone metastases. "
05/01/2006 - "To develop a radiopharmaceutical for the palliation of painful bone metastases based on the concept of bifunctional radiopharmaceuticals, we synthesized a bisphosphonate derivative labeled with rhenium-186 (186Re) that contains a hydroxyl group at the central carbon of its bisphosphonate structure, we attached a stable 186Re-MAMA chelate to the amino group of a 4-amino butylidene-bisphosphonate derivative [N-[2-[[4-[(4-hydroxy-4,4-diphosphonobutyl)amino]-4-oxobutyl]-2-thioethylamino]acetyl]-2-aminoethanethiolate] oxorhenium (V) (186Re-MAMA-HBP) and we investigated the effect of a hydroxyl group at the central carbon of its bisphosphonate structure on affinity for hydroxyapatite and on biodistribution by conducting a comparative study with [N-[2-[[3-(3,3-diphosphonopropylcarbamoyl)propyl]-2-thioethylamino]acetyl]-2-aminoethanethiolate] oxorhenium (V) (186Re-MAMA-BP). "
|5.||Dehydration (Water Stress)
|1.||Pentetic Acid (DTPA)
|2.||Protein Isoforms (Isoforms)
|4.||Carbonic Anhydrases (Carbonic Anhydrase)
|6.||rhenium sulfide (ReS2)
|7.||selenic acid (selenate)
|8.||selenocyanic acid (selenocyanate)
|9.||tellurous acid (tellurate)
|1.||Coronary Balloon Angioplasty (Percutaneous Transluminal Coronary Angioplasty)